Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sutro Biopharma, Inc. (STRO : NSDQ)

• Company Description    Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. Number of Employees: 137

• Price / Volume Information    Yesterday's Closing Price: $25.57 Daily Weekly Monthly 20 Day Moving Average: 284,058 shares Shares Outstanding: 16.57 (millions) Market Capitalization: $423.69 (millions) Beta: 1.63 52 Week High: $42.52 52 Week Low: $6.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.59% -30.17% 12 Week 24.91% 15.48% Year To Date 121.00% 143.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 111 Oyster Point Blvd. - South San Francisco,CA 94080 USA ph: 650-881-6500 fax: - ewhite@sutrobio.com http://www.sutrobio.com

• General Corporate Information    Officers Jane Chung - Chief Executive Officer Gregory Chow - Chief Financial Officer Michael Dybbs - Director Heidi Hunter - Director Sukhi Jagpal - Director Peer Information Sutro Biopharma, Inc. (CORR.) Sutro Biopharma, Inc. (RSPI) Sutro Biopharma, Inc. (CGXP) Sutro Biopharma, Inc. (BGEN) Sutro Biopharma, Inc. (GTBP) Sutro Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 869367201 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 16.57 Most Recent Split Date: 12.00 (0.10:1) Beta: 1.63 Market Capitalization: $423.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.92 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-9.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 46.57% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.25 EPS Growth vs. Year Ago Period: 67.69% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -16.53% vs. Previous Quarter: 24.69% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -69.20 12/31/25 - -79.02 09/30/25 - -73.44 Current Ratio 03/31/26 - 3.12 12/31/25 - 2.01 09/30/25 - 2.53 Quick Ratio 03/31/26 - 3.12 12/31/25 - 2.01 09/30/25 - 2.53 Operating Margin 03/31/26 - -154.21 12/31/25 - -186.45 09/30/25 - -206.77 Net Margin 03/31/26 - -154.21 12/31/25 - -186.45 09/30/25 - -206.77 Pre-Tax Margin 03/31/26 - -154.32 12/31/25 - -186.54 09/30/25 - -204.53 Book Value 03/31/26 - -4.04 12/31/25 - -15.43 09/30/25 - -10.26 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©